Plenary Session
AB071. SOH24AB_184. Evaluating preoperative neutrophil-lymphocyte ratio as a predictive biomarker in primary breast cancer
Alisha Jaffer1, Carolyn Cullinane2, Matthew Davey1, Burce Isik3, Amirhossein Jalali3, Juliette Buckley1, Chwanrow Baban1, Bridget Anne Merrigan1, Shona Tormey1
1Symptomatic Breast Unit, University Hospital Limerick, Dooradoyle, Limerick, Ireland;
2Department of General Surgery, University Hospital Waterford, Ballynakill, Waterford, Ireland;
3Faculty of Education & Health Services, School of Medicine, University of Limerick, Castletroy, Limerick, Ireland
Background: Neutrophil-lymphocyte ratio (NLR) is an established strong predictor of mortality in a variety of solid organ malignancies. Nevertheless, there is limited evidence supporting such in breast cancer. The aim of this work is to evaluate the association between preoperative NLR and breast cancer oncological and survival outcomes.
Methods: A retrospective cohort study was performed. Patients were identified from a prospectively maintained institutional database of breast cancer patients undergoing primary curative surgery at University Hospital Limerick from January 1, 2010 to June 1, 2017. Primary endpoints studied were disease-free survival (DFS) and overall survival (OS). Univariable and multivariable Cox regression examined survival outcomes between groups of patients with NLR <2.5 and NLR ≥2.5.
Results: After applying exclusion criteria, 579 patients were included. Median preoperative NLR was 2.63 (standard deviation: 1.42), with NLR ≥2.5 in 59.7% of patients (n=346). The mortality rate was 18.1% (n=105). The recurrence rate was 15.7% (n=91), with 6% local recurrence and 9.7% distant metastasis rates respectively at five years. Patients with NLR ≥2.5 were significantly associated with poorer OS [hazard ratio (HR): 1.71, 95% confidence interval (CI): 1.12–2.60, P=0.011], with equivocal outcomes observed for DFS (HR: 1.10, 95% CI: 0.91–1.34, P=0.300).
Conclusions: Preoperative NLR ≥2.5 was found to be an independent predictor of breast cancer OS. Prospective validation of these provisional results is required before incorporation into clinical practice to aid patient prognostication.
Keywords: Breast cancer; immunology; oncological outcomes; precision oncology; personalised medicine
Acknowledgments
Funding: None.
Conflicts of Interest: The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
doi: 10.21037/map-24-ab071
Cite this abstract as: Jaffer A, Cullinane C, Davey M, Isik B, Jalali A, Buckley J, Baban C, Merrigan BA, Tormey S. AB071. SOH24AB_184. Evaluating preoperative neutrophil-lymphocyte ratio as a predictive biomarker in primary breast cancer. Mesentery Peritoneum 2024;8:AB071.
